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INTRODUCTION
Charcot neuroarthropathy, also known as Charcot foot, is a com-
plication of diabetes mellitus where there is progressive degeneration 
of the joints, but it potentially is devastating in its consequences.1 It 
commonly affects the middle of the foot, hind-foot joints, the ankle, 
and forefoot joints, and it is believed to result from inflammation in 
the foot that becomes abnormally protracted due to the underlying 
neuropathy.2-8 The prevalence of Charcot neuroarthropathy is up to 
13% in individuals with diabetes.9-11 Patients with Charcot neuro-
arthropathy encounter increased morbidity and decreased quality 
of life and mortality.2,4,5,12,13 If there is a delay in treatment, Charcot 
neuroarthropathy could result in ulceration and infection which can 
lead to amputation of the limb.12-16 These patients have a significant 
financial impact on the health care system through primary care, 
community care, outpatient costs, increased bed occupancy, and 
prolonged stays in hospital.    
Charcot neuroarthropathy poses many clinical challenges in its 
diagnosis and management. The often asymptomatic nature of the 
condition is very similar to ankle sprain, cellulitis, venous thrombosis, 
inflammatory arthritis, or gout in a healthy patient.5,16-22 Missed diag-
nosis is as high as 79% which ultimately leads to a delay in treatment 
for an average of 29 weeks.11,16,17,20,23-25
Charcot neuroarthropathy is caused by multiple factors, but 
essentially it is the result of peripheral neuropathy which is a compli-
cation associated with many diseases.2,4,5 The underlying peripheral 
neuropathy can skew the pain perception the patient experiences 
and can mislead the clinician on their differential diagnosis of an 
“inflamed foot”.  A thorough neurological examination of the foot can 
uncover the underlying inflammatory and osteolytic disease process 
of Charcot neuroarthropathy.2,4,11,19,26-29  
Early recognition and intervention is imperative to avoid the 
rapid progression toward permanent foot deformity, ulceration, and 
the possibility of limb loss.16,30,31 There are multiple review articles 
about Charcot neuroarthropathy2,11-13,16,23,25,28,32-34, but a lack of guid-
ance on foot screen strategies for primary care and emergency room 
physicians. There is a need for a comprehensive guideline for initial 
diagnoses and management on foot care to advocate for increased 
awareness, thereby leading to earlier diagnosis and treatment by a 
multi-disciplinary team.  
In the current study, a thorough literature review of Charcot neu-
roarthropathy was conducted to evaluate efficacious methods of 
protocol design and potential barriers to implementation. The lit-
erature review also encompassed treatment goals for patients with 
Charcot neuroarthropathy. Based on the literature review, a foot 
screen strategies protocol for  Charcot neuroarthropathy was devised 
by the authors and reported here. This protocol contains three parts: 
(1) pathophysiology of acute Charcot neuroarthropathy to highlight 
the relationship between the clinical findings and the development 
of the disease, (2) a comprehensive guideline on how to screen and 
evaluate Charcot neuroarthropathy, and (3) a brief overview on pre-
vention of Charcot neuroarthropathy in patients with diabetes and 
other forms of peripheral neuropathy.
Pathophysiology. The underlying cause for Charcot neuroar-
thropathy is due to peripheral neuropathy, which is a loss of function 
of the nerves in the periphery of the body.2-4 The primary episode 
of inflammation can result from a number of factors, but ultimately 
leads to an increase in pro-inflammatory cytokines (interleukin-1β 
and tumor necrosis factor-α) which leads to receptor activator of the 
nuclear factor-κB ligand (RANKL-NFκB) pathway. Osteoclasts are 
activated leading to bone lysis followed by clearing of debris. In the 
presence of autonomic neuropathy, there is increased blood flow to 
the area, which acts to clear away bony material demineralizing the 
bone, cartilage, and soft tissue in the region.3 However, in the pres-
ence of diabetic neuropathy, the patient does not have the protective 
pain perception. Therefore, they continue to walk on the inflamed 
foot exacerbating the progressive pathway of osteolysis and osteo-
penia and weakening the pedal skeleton, leading to the high risk for 
dislocation and/or fracture.5-8,34,35 
Charcot neuroarthropathy screeningxguideline. Figure 1 
shows the step-by-step process from initial diagnosis of a patient pre-
senting with symptoms of an inflamed foot in a primary care setting 
to managing the patient with acute Charcot neuroarthropathy. The 
detailed pathway/algorithm for initial clinical diagnoses and man-
agement of acute Charcot neuroarthropathy should be divided into 
several phases: clinical assessment, peripheral neuropathy evalu-
ation, initial imaging and lab studies, diagnosis, management, and 
recommendation. Each phase includes the how, the why, and a step-
by-step guideline to making an early diagnosis easier and providing 
appropriate and immediate management for these patients.
Clinical assessment. A high degree of suspicion of Charcot 
neuroarthropathy is necessary with thorough history and physical 
examination when a patient presents with an acute erythematous, 
warm, or edematous foot, with or without any significant history of 
trauma or surgery, especially for patients with diabetes and periph-
eral neuropathy with these symptoms.36
History.xA thorough patient history of a traumatic event or 
peripheral neuropathy should be assessed. Approximately 50% of 
patients with Charcot neuroarthropathy would remember a pre-
cipitating, minor traumatic event, and if no traumatic episode was 
recalled, the time frame for which the patient noticed changes in 
their foot shape and/or gait should be documented. About 25% of 
patients develop similar changes in the contralateral foot.11,17,18,22,30,34,37-39
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not a traumatic event, but rather repetitive micro-trauma on an insen-
sate foot.11,17,18,29
A chronic history of diabetes longer than 10 years has a strong 
association with peripheral neuropathy and potential develop-
ment of Charcot neuropathy.11,12,34,40-44 Due to the strong association 
between elevated hemoglobin A1c (HbA1c) and the development of 
Charcot neuropathy, the patients’ compliance to their diabetic treat-
ment should be assessed and documented.2 Some patients also may 
be unaware of an underlying diagnosis of diabetes at the time of 
presentation, thereby diabetes screening is essential. Other poten-
tial causes of peripheral neuropathy also should be evaluated such 
as alcohol abuse, syringomyelia, spinal pathology, vitamin B12 defi-
ciency, heavy metal poisoning, leprosy, tertiary syphilis, and idiopathic 
form.2,3,8,45 Other potential risk factors that can lead to the develop-
ment of Charcot neuroarthropathy include obesity, advanced age, renal 
failure, iron deficiency, osteoporosis, and rheumatoid arthritis.2,3,8,45
Figure 1. Charcot neuroarthropathy screening and management guideline.
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       NEUROARTHROPATHY
          continued.
Physical examination. The classical physical examination find-
ings for an acute Charcot neuroarthropathy are often unilateral 
localized inflammatory symptoms of the foot, such as edema, ery-
thema, and increased foot temperature of the extremity.2-4,11,21,22,28,34,41 
A simple physical exam that can be helpful to distinguish between 
an infectious process and Charcot neuroarthropathy is to have 
the patient lay supine and elevate the affected extremity for 5 - 10 
minutes. Localized edema will decrease with elevation of the extrem-
ity in Charcot neuroarthropathy while an infectious process is less 
likely to decrease.11,46,47  
The infrared cutaneous temperature monitor to detect foot skin 
temperature changes is one of the most accurate tools for diagnosis 
acute Charcot neuroarthropathy. It may be used in the areas of fore-
foot, mid-foot, and hind-foot. A temperature difference of 2°C from 
the contralateral foot indicates an active Charcot neuroarthropa-
thy.48-50 
The presence of ulcers or a history of ulcers indicates the need to 
screen for an active infection. Signs and symptoms, such as puru-
lence, foul smell, or wet gangrene, should be noted.2,4,51 An ulcer with 
the size over 2 cm² and visualization of bone increases the risk of 
developing and/or presence of osteomyelitis.52,53  
Clinical assessments such as foot tenderness, pedal pulses, and 
foot deformity should be evaluated.2-4,11,21,22,28,34,41 Cutaneous changes 
such as increased sweating, calluses, and muscle atrophy should be 
documented.2 Owing to the possible presence of peripheral neu-
ropathy, pain may not always be present; with only 50% of patients 
reporting pain.28,36,37  
Charcot neuroarthropathy can present as an infectious process 
and screening of the patient’s vital signs for systemic signs of infec-
tion such as fever, chills, elevated heart rate or respiratory rate can 
be helpful.2,4,54 However, lack of these symptoms may not rule out an 
infectious process.
Peripheral neuropathy examination. The existence of little or 
no pain may mislead the patient and physician38, as peripheral neu-
ropathy is likely to be an essential prerequisite for the onset of the 
Charcot neuroarthropathy process. Bilateral neurologic examination 
should be assessed for numbness, paresthesia, and dysesthesia by 
evaluating cutaneous sensitivity using Semmes-Weinstein mono-
filament, proprioception, tuning fork vibration sensation, or Achilles 
tendon reflex (Figure 2).2,4,55-57 The Semmes-Weinstein monofila-
ment test is a noninvasive, low-cost, rapid, and easy-to-apply test 
that is the most sensitive test in diagnosing peripheral neuropathy.55,56 
The locations for this test on both feet include the first, third, and fifth 
metatarsal heads and plantar surface of the distal hallux and third 
toe, but avoid callused areas. Neuropathy usually starts in the first 
and third toes and progresses to the first and third metatarsal heads. 
Seven or less of 10 different touch sensation locations on the patient’s 
foot is an indication of peripheral neuropathy.52,56,58
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Imaging. Radiographs are the primary imaging method for initial 
evaluation of the foot in patients, as they provide information on bone 
structure, alignment, and mineralization.4,15,59,60 They also are useful 
in diagnosing the pathology, locating the area of involvement, evalu-
ating quality of bone, and identifying if the process is acute or chronic. 
It is essential to get plain radiographs on patients present with a 
symptomatic foot. Unfortunately, radiographic changes of Charcot 
neuroarthropathy typically are delayed and have low sensitivity. The 
plain radiographs can be negative for up to three weeks with the only 
finding being soft tissue swelling. Figure 3 shows an example of the 
Charcot neuroarthropathy progression on plain radiographs.
Figure 2. Neurologic examinations. (a) Semmes-Weinstein Monofilament 
test; (b) proprioception test on a big toe; (c) tuning fork vibration sensation 
test; and (d) Achilles reflex test using a reflex hammer.
The initial radiographic images should include anteroposterior 
and lateral weight-bearing views of the affected foot and/or full series 
ankle views (anteroposterior, mortise, and lateral views) depend-
ing on clinical suspicion.4,60,61 Evidence of demineralization, bone 
destruction, and periosteal reaction on plain radiographic images 
can lead towards a diagnosis of Charcot neuroarthropathy, although 
this also can be seen in chronic osteomyelitis.
If Charcot neuroarthropathy is suspected, magnetic resonance 
imaging (MRI) allows detection of subtle changes in the early 
stages when the plain radiographic images appears normal.25 MRI 
also is useful to rule out osteomyelitis, especially in the presence of 
an ulcer, history of ulcers, elevated erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), or leukocytosis.2,5,25,45,62-69 The 
sensitivity and specificity are reported greater than 77% and 80% 
respectively in differentiating acute Charcot neuroathropathy from 
osteomyelitis.2,45,62-68 Osteomyelitis on MRI often displays diffuse 
marrow involvement that usually only affects a single bone like the 
metatarsal heads and the calcaneus,4,70 whereas Charcot neuroar-
thropathy more classically exhibits periarticular and subchondral 
bone marrow edema affecting several joints.4,71
Bone scan is another imaging tool that can be used to differentiate 
osteomyelitis from Charcot neuroarthropathy. A technetium-99m 
methylene diphosphonate scintigraphy is less useful than leukocyte 
scintigraphy because there is enrichment on both osteomyelitis and 
Charcot neuroarthropathy, whereas leukocyte scintigraphy is only 
positive in osteomyelitis.2,62 The combination of technetium-99m 
methylene diphosphonate scintigraphy with indium-111 white blood 
cells, labeled leukocyte scintigraphy may improve sensitivity (87%) 
and specificity (81%) for differentiating acute Charcot neuroarthrop-
athy and osteomyelitis.4,59,72-75
Figure 3. Progression of a foot Charcot neuroarthropathy on plain radio-
graphs: (a) Initial anteroposterior  view of an acute  Charcot neuroarthropathy 
foot; (b) 6-month follow-up, which shows the persistent and progressive 
joint effusion, narrowing of the joint space, soft tissue calcification, minimal 
subluxation, osteopenia, and bone fragmentation; and (c) 2-year follow-up, 
which shows severe destruction of the foot without proper management.
Laboratory tests. There is a strong association between the dura-
tion of diabetes, elevated HbA1c, and the development of Charcot 
neuroarthropathy.9,11,76 The patient should be screened initially for 
uncontrolled diabetes by evaluating fasting glucose, HbA1c, and/or 
random glucose levels. Even if the patient has no known diabetes 
history, they should be screened because of the high prevalence of 
diabetes.25,33,77 If these lab values are not elevated and the patient has 
no known diabetes, then further evaluation should be made for the 
cause of peripheral neuropathy. 
Initial lab orders should include complete blood count (CBC) with 
a differential, erythrocyte sedimentation rate (ESR), and C-reactive 
protein (CRP). Elevations in ESR, CRP, and leukocytosis are more 
in line with an infectious process like osteomyelitis.2,3,34,78 An ESR 
greater than 70 mm/h has an 11-fold increased risk for the presence 
of osteomyelitis.52,79 A slight elevation in ESR with normal white 
blood cell count (WBC) may occur in Charcot neuroarthropa-
thy.80 Normal inflammatory markers may be noticed occasionally in 
chronic osteomyelitis; the diagnosis may depend on other modalities 
like radiographs and MRI.2,51 
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screen protocol is early management of these suspected Charcot 
neuroarthropathy patients. Many cases of acute Charcot neuroar-
thropathy are mistreated because the condition is not recognized 
widely outside specialist clinics. If the suspected Charcot neuroar-
thropathy is complicated by ulceration or infection, then an inpatient 
treatment plan should be implemented before sending the patient 
home. The gold standard of conservative management strategy for 
Charcot neuroarthropathy has been immobilization and non-weight 
bearing.81
Inpatient treatment plan. Patients with confirmed or suspected 
infection, such as cellulitis, deep tissue infection, abscess or osteo-
myelitis, should be admitted for evaluation, when they have at least 
two of the following criteria from Systemic Inflammatory Response 
Syndrome (SIRS): body temperature ≥ 38°C or < 36°C, heart rate 
> 90 beats/minute, respiratory rate > 20 breaths/min. or arterial 
carbon dioxide tension (PaCO2) < 32 mmHg, abnormal white blood 
cell count ≥ 12,000/μL or ≤ 4,000/μL or > 10% immature (bands) 
forms.82-84 Infection in the Charcot neuroarthropathy patient poses 
great challenges. Discussion with a foot and ankle specialist is recom-
mended about treatment plans such as irrigation and debridement, 
culture/biopsy of the wound, and antibiotic treatment. Immobiliza-
tion of the affected foot continues until complete resolution of the 
acute phase. Patient education regarding the diagnosis, estimated 
length of treatment, and expected outcomes is an important com-
ponent of Charcot neuroarthropathy management. If the patient 
understands the nature of this limb-threatening condition, they may 
be more motivated to adhere to the management plan. Emphasis on 
the importance of strict immobilization and attending regular follow-
up reviews may improve the outcome of Charcot neuroarthropathy.
Initial clinical treatment. The initial clinical treatment for a 
patient suspected of Charcot neuroarthropathy should be immobili-
zation and non-weight bearing of affected foot.2,4,11,15,81,85-87 The goals 
are to stop the inflammation-mediated damage, relieve pain, and 
maintain or protect the skeleton of the foot and ankle from further 
deformity on the affected limb until definitive diagnosis can be made. 
The use of a total contact cast (TCC; Figure 4), instant total contact 
cast (iTCC) with the use of crutches, or a knee scooter is recom-
mended. If the clinician has limited experience in the application of 
TCC or iTCC, they can immobilize the patient in a short leg splint 
with a clear understanding that this is not the definitive treatment 
for immobilization. A wheelchair should be prescribed in cases where 
there is clinical suspicion of non-compliance or a question of bilat-
eral involvement. These treatments are not definitive and the patient 
should be referred to a foot and ankle specialist (orthopedic or podia-
trist) to establish a multidisciplinary team approach for definitive 
treatment.
       DIAGNOSIS AND MANAGEMENT FOR CHARCOT  
       NEUROARTHROPATHY
           continued.
Figure 4. Total contact cast (TCC).
Preventive medicine. Patients with diabetes mellitus and mild-
to-severe peripheral neuropathy have high potential of developing 
Charcot neuroarthropathy. It affects 415 million people globally. 
This number is predicted to rise to 642 million by 2040.88 These 
patients have a significant impact on health care costs, so prevention 
is important.11,25,76,89 Like most complications of diabetes, the key is 
to control patients’ glucose and HbA1c levels either by diet and/or 
medication.90 The American Diabetes Association 2016 guidelines90 
recommended a glycemic target of HbA1c < 7.0% (53 mmol/mol), 
preprandial capillary plasma glucose of 80 - 130 mg/dL (4.4 - 7.2 
mmol/L), and peak postprandial capillary plasma glucose < 180 mg/
dL (10 mmol/L) for non-pregnant adults. 
Patient education is an essential component of the long-term 
management, focusing on the importance of appropriate footwear, 
offloading, regular follow up reviews, and the risk of further com-
plications.27,28 Lifestyle changes for obesity, nutrition, smoking and 
alcohol abuse should be addressed.2 A thorough diabetic foot exam 
to check for any skin abnormalities and a neurological exam should 
be performed at least two times a year, if the patient shows signs of 
peripheral neuropathy. It is recommended that the patient be pre-
scribed a hard shoe, diabetic foot wear, or foot orthoses, and advised 
against wearing sandals to prevent development of Charcot neuro-
arthropathy. Footwear is an important component of the long-term 
management of the insensate chronic Charcot neuroarthropathy, 
ensuring that it remains accommodated and protected. Patients 
should be educated on regular self-examinations of their feet for skin 
break down, swelling, erythema and ulcers, and encouraged to evalu-
ate their shoes for any foreign bodies before putting them on.
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CONCLUSION
A thorough neurological examination must be a part of the 
physical exam for any patient presenting with unilateral erythema, 
edema, and increased foot temperature that has high risk factors for 
peripheral neuropathy. This examination could prevent any hidden 
inflammatory process, like Charcot neuroarthropathy, from going 
undiagnosed. A protocol for primary care and emergency room 
physicians provides a comprehensive guideline on foot screening, 
especially for acute Charcot neuroarthropathy.
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